Matinas Biopharma (MTNB) Competitors $1.75 +0.02 (+1.16%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.75 +0.00 (+0.06%) As of 09/19/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. RANI, DYAI, IMA, JATT, KLTO, XFOR, MTVA, OKUR, ITRM, and MAAQShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Rani Therapeutics (RANI), Dyadic International (DYAI), ImageneBio (IMA), JATT Acquisition (JATT), Klotho Neurosciences (KLTO), X4 Pharmaceuticals (XFOR), MetaVia (MTVA), OnKure Therapeutics (OKUR), Iterum Therapeutics (ITRM), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors Rani Therapeutics Dyadic International ImageneBio JATT Acquisition Klotho Neurosciences X4 Pharmaceuticals MetaVia OnKure Therapeutics Iterum Therapeutics Mana Capital Acquisition Rani Therapeutics (NASDAQ:RANI) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Which has higher earnings and valuation, RANI or MTNB? Matinas Biopharma has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$1.03M35.93-$30.02M-$0.91-0.57Matinas BiopharmaN/AN/A-$22.94M-$3.89-0.45 Is RANI or MTNB more profitable? Matinas Biopharma's return on equity of -123.06% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -1,258.76% -97.97% Matinas Biopharma N/A -123.06%-94.28% Does the media prefer RANI or MTNB? In the previous week, Rani Therapeutics' average media sentiment score of 0.00 equaled Matinas Biopharma'saverage media sentiment score. Company Overall Sentiment Rani Therapeutics Neutral Matinas Biopharma Neutral Which has more volatility & risk, RANI or MTNB? Rani Therapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Do analysts recommend RANI or MTNB? Rani Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 1,324.22%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of RANI or MTNB? 30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 45.1% of Rani Therapeutics shares are held by insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryRani Therapeutics beats Matinas Biopharma on 7 of the 12 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$8.90M$859.72M$5.77B$21.65BDividend YieldN/A4.84%5.61%3.51%P/E Ratio-0.361.2380.5029.94Price / SalesN/A120.98456.1860.02Price / CashN/A19.5637.6624.98Price / Book0.406.7015.754.59Net Income-$22.94M-$4.03M$3.30B$1.00B7 Day Performance-4.37%-1.12%5.35%0.81%1 Month Performance0.57%7.43%7.28%5.30%1 Year PerformanceN/A19.64%80.79%14.58% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas Biopharma0.0484 of 5 stars$1.75+1.2%N/AN/A$8.90MN/A-0.3630Negative NewsGap UpRANIRani Therapeutics2.6672 of 5 stars$0.49+0.2%$7.33+1,399.7%-78.0%$35.14M$1.03M-0.54110DYAIDyadic International2.7786 of 5 stars$0.96-0.2%$6.00+522.4%-14.4%$34.89M$3.49M-5.077IMAImageneBio2.5734 of 5 stars$8.59-4.1%$35.50+313.3%-59.8%$34.53M$9.16M-1.1270High Trading VolumeJATTJATT AcquisitionN/A$2.00-1.0%N/A-53.7%$34.50MN/A0.003High Trading VolumeKLTOKlotho Neurosciences0.1168 of 5 stars$0.56-4.4%N/AN/A$34.36MN/A-1.24N/AXFORX4 Pharmaceuticals4.2869 of 5 stars$2.94-1.7%$34.17+1,062.1%-85.1%$33.78M$32.77M-0.2080MTVAMetaVia1.7701 of 5 stars$1.33-11.5%$7.50+464.8%N/A$32.14MN/A0.008News CoverageHigh Trading VolumeOKUROnKure Therapeutics2.7969 of 5 stars$2.35-1.6%$32.33+1,275.3%N/A$32.07MN/A-0.49N/ANews CoveragePositive NewsITRMIterum Therapeutics2.5242 of 5 stars$0.67-1.5%$9.00+1,235.3%-36.5%$31.70MN/A-0.7910News CoverageShort Interest ↓Gap UpMAAQMana Capital AcquisitionN/A$3.79-0.9%N/A+1,326.0%$30.79MN/A0.001Gap Up Related Companies and Tools Related Companies RANI Alternatives DYAI Alternatives IMA Alternatives JATT Alternatives KLTO Alternatives XFOR Alternatives MTVA Alternatives OKUR Alternatives ITRM Alternatives MAAQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTNB Stock Alerts